PACB241220C1000
- 0.80
- 0.000.00%
Pacific Biosciences of California Newsroom
Pacific Biosciences Price Target Announced at $2.00/Share by UBS
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $6
Pacific Biosciences Is Maintained at Neutral by Piper Sandler
Pacific Biosciences Analyst Ratings
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2.5
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $4
Barclays Reaffirms Their Hold Rating on Pacific Biosciences (PACB)
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
Pacific Biosciences Analyst Ratings
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $7
Pacific Biosciences (PACB) Receives a Buy From Scotiabank
Morgan Stanley Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $2.5
Piper Sandler Reaffirms Their Hold Rating on Pacific Biosciences (PACB)
Pacific Biosciences Analyst Ratings
Piper Sandler Keeps Their Hold Rating on Pacific Biosciences (PACB)
Pacific Biosciences Analyst Ratings
Pacific Biosciences: A Buy Rating Amidst Recovery and Growth Potential
Critical Insights From Pacific Biosciences Analyst Ratings: What You Need To Know